CND Life Sciences has announced that its Syn-One Test was able to identify the pathological form of alpha-synuclein in the skin of more than 95% of patients diagnosed with synucleinopathy in the Synuclein-One study.
Synucleinopathies are a group of disorders with worsening neurological deficits. Patients with synucleinopathies are diagnosed with conditions such as Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies and pure autonomic failure.
